메뉴 건너뛰기




Volumn 120, Issue 1, 2014, Pages 77-85

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

Author keywords

antiangiogenic; cetuximab; everolimus; pharmacodynamic; phase 1

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CETUXIMAB; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GADODIAMIDE; MAMMALIAN TARGET OF RAPAMYCIN;

EID: 84890794963     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28294     Document Type: Article
Times cited : (22)

References (40)
  • 1
    • 79955513633 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
    • Brand TM, Iida M, Wheeler DL,. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011; 11: 777-792.
    • (2011) Cancer Biol Ther , vol.11 , pp. 777-792
    • Brand, T.M.1    Iida, M.2    Wheeler, D.L.3
  • 2
    • 33646228635 scopus 로고    scopus 로고
    • KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    • et al
    • Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66: 3992-3995.
    • (2006) Cancer Res , vol.66 , pp. 3992-3995
    • Lièvre, A.1    Bachet, J.B.2    Le Corre, D.3
  • 3
    • 0035394833 scopus 로고    scopus 로고
    • Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis
    • Viloria-Petit A, Crombet T, Jothy S, et al. Resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2000; 61: 5090-5101. (Pubitemid 32681540)
    • (2001) Cancer Research , vol.61 , Issue.13 , pp. 5090-5101
    • Viloria-Petit, A.1    Crombet, T.2    Jothy, S.3    Hicklin, D.4    Bohlen, P.5    Schlaeppi, J.M.6    Rak, J.7    Kerbel, R.S.8
  • 4
    • 38149015503 scopus 로고    scopus 로고
    • PI3K/PTEN signaling in tumorigenesis and angiogenesis
    • Jiang BH, Liu LZ,. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta. 2007; 1784: 150-158.
    • (2007) Biochim Biophys Acta , vol.1784 , pp. 150-158
    • Jiang, B.H.1    Liu, L.Z.2
  • 5
    • 63449098382 scopus 로고    scopus 로고
    • MTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor
    • et al
    • Lane HA, Wood JM, McSheehy PM, et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 2009; 15: 1612-1622.
    • (2009) Clin Cancer Res , vol.15 , pp. 1612-1622
    • Lane, H.A.1    Wood, J.M.2    McSheehy, P.M.3
  • 7
    • 56849096837 scopus 로고    scopus 로고
    • HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
    • et al
    • Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14: 435-446.
    • (2008) Cancer Cell , vol.14 , pp. 435-446
    • Gordan, J.D.1    Lal, P.2    Dondeti, V.R.3
  • 9
    • 34547605613 scopus 로고    scopus 로고
    • IKKbeta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway
    • et al
    • Lee DF, Kuo HP, Chen CT, et al. IKKbeta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 2007; 130: 440-455.
    • (2007) Cell , vol.130 , pp. 440-455
    • Lee, D.F.1    Kuo, H.P.2    Chen, C.T.3
  • 10
    • 33644529055 scopus 로고    scopus 로고
    • ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells
    • et al
    • Klos KS, Wyszomierski SL, Sun M, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 2006; 66: 2028-2037.
    • (2006) Cancer Res , vol.66 , pp. 2028-2037
    • Klos, K.S.1    Wyszomierski, S.L.2    Sun, M.3
  • 11
    • 0032757213 scopus 로고    scopus 로고
    • 18F]- fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations
    • DOI 10.1016/S0959-8049(99)00229-4, PII S0959804999002294
    • Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35: 1773-1782. (Pubitemid 29512308)
    • (1999) European Journal of Cancer , vol.35 , Issue.13 , pp. 1773-1782
    • Young, H.1    Baum, R.2    Cremerius, U.3    Herholz, K.4    Hoekstra, O.5    Lammertsma, A.A.6    Pruim, J.7    Price, P.8
  • 12
    • 55749109991 scopus 로고    scopus 로고
    • Respiratory motion-compensated radial dynamic contrast-enhanced (DCE)-MRI of chest and abdominal lesions
    • et al
    • Lin W, Guo J, Rosen MA, et al. Respiratory motion-compensated radial dynamic contrast-enhanced (DCE)-MRI of chest and abdominal lesions. Magn Reson Med. 2008; 60: 1135-1146.
    • (2008) Magn Reson Med , vol.60 , pp. 1135-1146
    • Lin, W.1    Guo, J.2    Rosen, M.A.3
  • 13
    • 0033646318 scopus 로고    scopus 로고
    • K-Space weighted image contrast (KWIC) for contrast manipulation in projection reconstruction MRI
    • Song HK, Dougherty L,. k-Space weighted image contrast (KWIC) for contrast manipulation in projection reconstruction MRI. Magn Reson Med. 2000; 44: 825-832.
    • (2000) Magn Reson Med , vol.44 , pp. 825-832
    • Song, H.K.1    Dougherty, L.2
  • 16
    • 2142641698 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
    • DOI 10.1200/JCO.2004.10.182
    • Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that express the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 1201-1208. (Pubitemid 41079832)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.7 , pp. 1201-1208
    • Saltz, L.B.1    Meropol, N.J.2    Loehrer Sr., P.J.3    Needle, M.N.4    Kopit, J.5    Mayer, R.J.6
  • 17
    • 43249086546 scopus 로고    scopus 로고
    • Phase i pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    • et al
    • O'Donnell A, Faivre S, Burris HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1588-1595.
    • (2008) J Clin Oncol , vol.26 , pp. 1588-1595
    • O'Donnell, A.1    Faivre, S.2    Burris, H.A.3
  • 19
    • 0346752528 scopus 로고    scopus 로고
    • Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours
    • DOI 10.1038/sj.bjc.6601386
    • Checkley D, Tessier JJ, Kendrew J, et al. Use of dynamic contrast enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signaling inhibitor, in PC-3 prostate tumors. Br J Cancer. 2003; 89: 1889-1895. (Pubitemid 37533265)
    • (2003) British Journal of Cancer , vol.89 , Issue.10 , pp. 1889-1895
    • Checkley, D.1    Tessier, J.J.2    Kendrew, J.3    Waterton, J.C.4    Wedge, S.R.5
  • 23
    • 67649946279 scopus 로고    scopus 로고
    • Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study
    • et al
    • Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009; 20: 27:3027-3035.
    • (2009) J Clin Oncol , vol.20 , pp. 273027-273035
    • Zhu, A.X.1    Sahani, D.V.2    Duda, D.G.3
  • 24
    • 58149136153 scopus 로고    scopus 로고
    • Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy
    • et al
    • Wang X, Hawk N, Yue P, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther. 2008; 7: 1952-1958.
    • (2008) Cancer Biol Ther , vol.7 , pp. 1952-1958
    • Wang, X.1    Hawk, N.2    Yue, P.3
  • 25
    • 1642535579 scopus 로고    scopus 로고
    • Roles of Phosphatidylinositol 3′-Kinase and Mammalian Target of Rapamycin/p70 Ribosomal Protein S6 Kinase in K-Ras-Mediated Transformation of Intestinal Epithelial Cells
    • DOI 10.1158/0008-5472.CAN-03-1859
    • Shao J, Evers BM, Sheng H,. Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res. 2004; 64: 229-235. (Pubitemid 38114103)
    • (2004) Cancer Research , vol.64 , Issue.1 , pp. 229-235
    • Shao, J.1    Evers, B.M.2    Sheng, H.3
  • 26
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial
    • et al
    • Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 28
    • 80555126830 scopus 로고    scopus 로고
    • Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
    • et al
    • Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011; 117: 5094-5102.
    • (2011) Cancer , vol.117 , pp. 5094-5102
    • Zhu, A.X.1    Abrams, T.A.2    Miksad, R.3
  • 29
    • 44649105082 scopus 로고    scopus 로고
    • Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma
    • et al
    • Piguet AC, Semela D, Keogh A, et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol. 2008; 49: 78-87.
    • (2008) J Hepatol , vol.49 , pp. 78-87
    • Piguet, A.C.1    Semela, D.2    Keogh, A.3
  • 30
    • 33644546368 scopus 로고    scopus 로고
    • Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors
    • et al
    • Amin DN, Hida K, Bielenberg DR, et al. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 2006; 66: 2173-2180.
    • (2006) Cancer Res , vol.66 , pp. 2173-2180
    • Amin, D.N.1    Hida, K.2    Bielenberg, D.R.3
  • 33
    • 84857734054 scopus 로고    scopus 로고
    • Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer
    • et al
    • Yoo DS, Kirkpatrick J, Craciunescu O, et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res. 2012; 18: 1404-1414.
    • (2012) Clin Cancer Res , vol.18 , pp. 1404-1414
    • Yoo, D.S.1    Kirkpatrick, J.2    Craciunescu, O.3
  • 34
    • 78650614425 scopus 로고    scopus 로고
    • Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
    • et al
    • Pantaleo MA, Nicoletti G, Nanni C, et al. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. J Exp Clin Cancer Res. 2010; 29: 173.
    • (2010) J Exp Clin Cancer Res , vol.29 , pp. 173
    • Pantaleo, M.A.1    Nicoletti, G.2    Nanni, C.3
  • 35
    • 79851472656 scopus 로고    scopus 로고
    • 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model
    • et al
    • Aide N, Kinross K, Cullinane C, et al. 18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model. J Nucl Med. 2010; 51: 1559-1564.
    • (2010) J Nucl Med , vol.51 , pp. 1559-1564
    • Aide, N.1    Kinross, K.2    Cullinane, C.3
  • 36
    • 70350719369 scopus 로고    scopus 로고
    • Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus
    • et al
    • Nogova L, Boellaard R, Kobe C, et al. Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med. 2009; 50: 1815-1819.
    • (2009) J Nucl Med , vol.50 , pp. 1815-1819
    • Nogova, L.1    Boellaard, R.2    Kobe, C.3
  • 37
    • 84866918066 scopus 로고    scopus 로고
    • FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer (mRCC)
    • et al.: Abstract
    • Chen JL, Appelbaum DE, Kocherginsky M, et al. FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer (mRCC). J Clin Oncol. 2011; 29 (suppl): Abstract e15047.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Chen, J.L.1    Appelbaum, D.E.2    Kocherginsky, M.3
  • 38
    • 66849095262 scopus 로고    scopus 로고
    • [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy
    • et al
    • Ma WW, Jacene H, Song D, et al. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009; 27: 2697-2704.
    • (2009) J Clin Oncol , vol.27 , pp. 2697-2704
    • Ma, W.W.1    Jacene, H.2    Song, D.3
  • 39
    • 84865562515 scopus 로고    scopus 로고
    • Phase i safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
    • et al
    • Markman B, Tabernero J, Krop I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012; 23: 2399-2408.
    • (2012) Ann Oncol , vol.23 , pp. 2399-2408
    • Markman, B.1    Tabernero, J.2    Krop, I.3
  • 40
    • 43249131245 scopus 로고    scopus 로고
    • Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase i tumor pharmacodynamic study in patients with advanced solid tumors
    • et al
    • Tabernero J, Rojo F, Calvo E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol. 2008; 26: 1603-1610.
    • (2008) J Clin Oncol , vol.26 , pp. 1603-1610
    • Tabernero, J.1    Rojo, F.2    Calvo, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.